Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.
|Videos|February 4, 2022
Pharmaceutical Executive Roundtable: Future Shaping in Sales and Marketing: Regional Marketing Manager
In this segment, members of the panel discuss consolidation of practices and managing business from a field perspective focusing on understanding the needs and insights of customer groups. Where is it needed?
Advertisement
Advertisement
Related to this article
Waiting for perfect data before deploying AI is a trap — and why 60-70% accuracy is often good enough to start.
Fox Rothschild's Marc Wagner on why the FDA counts 70 drugs in shortage while ASHP counts 188 — and what's driving the gap.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.
Advertisement
Advertisement
Trending on PharmExec
1
Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts
2
The Bottlenecks That Slow Manufacturer Response to Increased Demand for Production
3
The Manufacturing Issues That Continue to Contribute to Drug Shortages
4
Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeutics Enters Collaboration and License Agreement to Develop Sec61-Targeting Small Molecules
5